Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Study Of Rx TV Ads Should Recruit Participants More Broadly, Firms Say

Executive Summary

Industry is recommending that FDA modify the recruitment strategies for its study of Rx TV ads and represent more diseases in sample ads shown to participants in order to facilitate more comprehensive and efficient data collection

You may also be interested in...

FDA Expands Advisory Cmte. Disclosures As Congress Directs Conflict Reductions

FDA's draft guidance on the procedure for disclosing conflicts of interest will extend the agency's disclosure policy to cover all advisory committee members

DTC Fines May Be More Useful To Advertising Opponents Than An FDA Ban

Opponents of direct-to-consumer television ads will be better off with FDA having authority to fine companies for false and misleading television ads than they would have been if the agency was given the power to simply ban such ads, according to Scott Lassman, former Senior Assistant General Counsel at Pharmaceutical Research and Manufacturers of America

Rx TV Ads To Get FDA Study On How Visual Cues May Distract From Audio Risks

Data collection in an FDA study of how the audio, visual and textual components of a television ad affect a viewer's intake of information and perception of a drug's risks and benefits is expected to begin in May 2008

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts